NIH scientists have demonstrated a promising approach using patients' own immune cells to fight gastrointestinal cancers, with tumor shrinkage observed in about 25% of trial participants.
A pioneering clinical trial at the US National Cancer Institute using Tumor Infiltrating Lymphocytes (TIL) therapy successfully eliminated stage 4 breast cancer in patient Judy Perkins, marking a significant breakthrough in immunotherapy.
Leading oncologists predict immunotherapy may expand into cancer prevention for high-risk lung cancer patients, potentially revolutionizing early intervention strategies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.